In this review, we consider how polygenic risk scores may be informative at different points in the disease trajectory, from unaffected individuals being tested for future disease risk to diagnosed patients, assessing how genetic information might inform their treatment or provide prognostic information on disease course. For each stage, we illustrate how PRS might be used and give examples of the current progress in the field.
